Coffee, Tea May Be Protective Against Liver Cancer
(MedPage Today) -- Certain dietary habits such as higher alcohol intake were associated with a higher risk of hepatocellular carcinoma (HCC), while others such as coffee and tea drinking were linked with a lower risk, according to a large Mendelian... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - June 10, 2022 Category: Gastroenterology Source Type: news

Positive Topline Results for Novel Probiotic in Autism Positive Topline Results for Novel Probiotic in Autism
An investigational probiotic is safe with a hint of clinical benefit in individuals with autism, results from an early phase 1b trial suggest.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - June 10, 2022 Category: Gastroenterology Tags: Psychiatry News Source Type: news

Stigma in Nonalcoholic Fatty Liver Disease Little Studied Stigma in Nonalcoholic Fatty Liver Disease Little Studied
Almost 7 in 10 patients with this relatively new syndrome report experiencing stigmatization in their daily lives.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - June 10, 2022 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

New IMBRUVICA ® (ibrutinib) Data in Fixed-Duration Combination Regimen Presented at EHA 2022 Shows Deep, Durable Response at Three Years in Untreated Chronic Lymphocytic Leukemia
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new and updated results from the Phase 2 CAPTIVATE study evaluating IMBRUVICA® (ibrutinib) in combination with venetoclax (I+V) as a potential fixed-duration (FD) treatment in adult patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Updated data from the FD cohort with three years of follow-up shows that I+V continues to demonstrate deep and durable responses and clinically meaningful progression-free survival (PFS) and overall survival (OS) in the first-line tre...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Bariatric Surgery Cuts Obesity - Related Cancer Incidence
Findings seen in large study of obese adults with and without surgery, followed for 10 years (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 9, 2022 Category: Cancer & Oncology Tags: Family Medicine, Gastroenterology, Internal Medicine, Oncology, Surgery, Journal, Source Type: news

New Drug Launch Prices Increasing Exponentially Each Year
Findings among newly marketed brand - name prescription drugs launched in 2008 to 2021 (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - June 9, 2022 Category: Respiratory Medicine Tags: Cardiology, Dermatology, Endocrinology, Family Medicine, Geriatrics, Gastroenterology, Gynecology, Infections, AIDS, Internal Medicine, Allergy, Nephrology, Neurology, Oncology, Ophthalmology, Orthopedics, ENT, Pediatrics, Pharmacy, Psychiatry, Pulmonolog Source Type: news

Additional Biopsies After CRC Biopsy Not Tied to Metachronous CRC
Biopsy of nontumor sites after initial colorectal cancer biopsy not linked to risk for metachronous cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 9, 2022 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pathology, Journal, Source Type: news

Additional Biopsies After CRC Biopsy Not Tied to Metachronous CRC
THURSDAY, June 9, 2022 -- There is no significant association between metachronous cancer and biopsy of nontumor sites after biopsy of a primary colorectal cancer (CRC), according to a study published online May 26 in Clinical Gastroenterology and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 9, 2022 Category: Pharmaceuticals Source Type: news

' Underwhelming' Improvements in mCRC Overall Survival'Underwhelming' Improvements in mCRC Overall Survival
Overall survival for patients with metastatic colorectal cancer has improved over recent decades with the introduction of novel systemic therapies, but the gains have been modest at best, say experts.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 9, 2022 Category: Cancer & Oncology Tags: Gastroenterology News Source Type: news

CRC Screening During COVID; Kids' Unusual Hepatitis Hits 38 States; NAFLD & the Gut
(MedPage Today) -- Colonoscopies for colorectal cancer (CRC) fell during the first year of the pandemic, but the decrease was attenuated by increases in stool-based CRC screening, according to a national survey. (JAMA Network Open) As of June... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - June 9, 2022 Category: Gastroenterology Source Type: news

Celiac Disease and IBD Show Strong Bidirectional Link Celiac Disease and IBD Show Strong Bidirectional Link
After the first year postdiagnosis, patients with celiac disease had an almost 4-fold higher risk of IBD, and patients with IBD had more than a 5-fold higher risk of celiac disease.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - June 9, 2022 Category: Allergy & Immunology Tags: Gastroenterology News Source Type: news

European Commission approves Roche ’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
In the Phase III IMpower010 trial, adjuvantTecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resected Stage II-III NSCLC, compared with best supportive careTecentriq is now the firstand only cancer immunotherapy available for certain people with early-stage NSCLC in EuropeToday ’s approval marksTecentriq ’s sixth lung cancer indication in EuropeBasel, 09 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) as an adjuvant treatment, following complete resection and platinum-based chemotherapy, for adu...
Source: Roche Investor Update - June 9, 2022 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
In the Phase III IMpower010 trial, adjuvantTecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resected Stage II-III NSCLC, compared with best supportive careTecentriq is now the firstand only cancer immunotherapy available for certain people with early-stage NSCLC in EuropeToday ’s approval marksTecentriq ’s sixth lung cancer indication in EuropeBasel, 09 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) as an adjuvant treatment, following complete resection and platinum-based chemotherapy, for adu...
Source: Roche Media News - June 9, 2022 Category: Pharmaceuticals Source Type: news

10 Highlights From Digestive Disease Week 2022 10 Highlights From Digestive Disease Week 2022
With a focus on newly approved treatments and those seemingly on the verge, this year ' s meeting had clear practice-changing implications, says Dr David Johnson.Medscape Gastroenterology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - June 9, 2022 Category: Allergy & Immunology Tags: Gastroenterology Commentary Source Type: news

Intensified Regimen for Metastatic CRC Fails to Improve Outcomes
(MedPage Today) -- CHICAGO -- For metastatic colorectal cancer patients with RAS and BRAF wild-type disease, intensifying the upfront chemotherapy backbone in combination with the anti-EGFR antibody panitumumab (Vectibix) provided no additional... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - June 9, 2022 Category: Gastroenterology Source Type: news